



R0144B

B2/B3

31033A/17 B02 TAKEDA CHEMICAL IND KK 25.08.76-JA-101923 (16.03.78) A61k-31/50 C07d-239/54 C07d-	TAKE 25.08.76 *J5 3028-192 B(6-F3, 7-D12, 12-A1, 12-D7, 12-E8, 12-F5, 12-G1, 12-G3). 7 89
Pyrimido (4,5-e) (1,3,4)thiadiazine derivs. - with hypotensive, diuretic, antiinflammatory, gastric secretion inhibiting and cyclic-AMP phosphodiesterase inhibiting activity	(such as human, dog, rabbit, rat and mouse), hypotensive, diuretic, antiinflammatory and gastric secretion inhibitory activities and are useful as anti-hypertensive, diuretic, antiinflammatory and antiulcer remedies as well as antibacterials and biochemical reagents.
(A) Pyrimido [4,5-e] [1,3,4]thiadiazine derivs. of formula (I) and salts thereof are new:	PREPARATION
 <p style="text-align: center;">(I)</p>	 <p style="text-align: center;">(II)</p>
(R <sup>1</sup> , R <sup>2</sup> = H or alkyl; R <sup>3</sup> = H, alkyl, alkenyl, opt. substd. aryl, aralkyl or acyl; R <sup>4</sup> = H, alkyl or acyl; provided R <sup>1</sup> , R <sup>2</sup> = alkyl when R <sup>4</sup> = acyl).	The oxidation is carried out with oxidizing agent pref. N-chlorosuccinimide at ca. 1-4 (pref. ca. 1-2) mol. on (II) in a solvent at 0-50 (pref. 20-30)° C for 0.5-10 (pref. 1-3) hrs. (R <sup>4</sup> = H, alkyl).
(B) Uracil deriv. intermediates of formula (II) (see "Preparation") are new.	EXAMPLE
USE (I) and salts exhibit c-AMP phosphodiesterase inhibition, histamine H <sub>2</sub> -receptor inhibition and, esp. to mammals	1,3-Dimethyl-6-(4-ethylthiosemicarbazido)uracil (40 g) is 31033A J530281 92+